

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	23
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	39
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	42
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	45
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Brazil (Latin America)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.31	0.42	0.55
Year of IDU prevalence estimate	2005		
Reference for IDU prevalence estimate	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B30000		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	18	48	78
Year of HIV prevalence among IDU estimate	2000		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	128 738 842 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	398 000	540 500	706 500
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	71 640	259 440	551 070

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other NSP indicators
When were NSPs first introduced?	1989
Reference	World Health Organization Western Pacific Region (2009). Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam: An application of selected human rights principles.
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

NSP 2: Number of NSP sites

Data reported	By 2006 there were about 150 needle and syringe exchange programs in the country 450 sites		
Year of reported data	2006 2008		
Reference	Rossi, D., S. Harris, et al. (2009). The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs". Open Society Institute – International Harm Reduction Development Program. New York. World Health Organisation (2009). Global health ATLAS data.		
Adjustments	- Date uncertain for UA data, assumed to be 2008		
Final/Adjusted data (to be used as indicator numerator)	150 - 450		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	0.21	0.56	1.13

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2006		
Reference	Rossi, D., S. Harris, et al. (2009). The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs". Open Society Institute – International Harm Reduction Development Program. New York. da Fonseca, E. M., J. M. Ribeiro, et al. (2006). "Syringe exchange programs in Brazil: preliminary assessment of 45 programs." Cadernos de Saude Publica 22(4): 761-70.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < ">http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	125 196 545 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	NK	NK	NK

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	NSP present but number not known		
Year of reported data	2006		
Reference	Rossi, D., S. Harris, et al. (2009). The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs". Open Society Institute – International Harm Reduction Development Program. New York. da Fonseca, E. M., J. M. Ribeiro, et al. (2006). "Syringe exchange programs in Brazil: preliminary assessment of 45 programs." Cadernos de Saude Publica 22(4): 761-70.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < ">http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	125 196 545 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	NK	NK	NK

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	126 452 syringes distributed from 45 out of 134 harm reduction programs operating in the country at the time		
Year of reported data	2004		
Reference	da Fonseca, E. M., J. M. Ribeiro, et al. (2006). "Syringe exchange programs in Brazil: preliminary assessment of 45 programs." <i>Cadernos de Saude Publica</i> 22(4): 761-70.		
Adjustments	For lower bound use data from sites reporting only For upper bound assume rate of distribution for these 45 sites reporting data the is same as average for remaining 89 sites		
Final/Adjusted data (to be used as indicator numerator)	126 452 - 376 546		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	121 421 994 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	0.19	0.5	1.00

NSP: All documents reviewed

Aparecida, M. and C. Teixeira (2006). "A capture-recapture technique to estimate the size of the injecting drug user population attending syringe exchange programs: AJUDE-Brasil II Project." *Cadernos de Saúde Pública* 22(4): 783-9.

AVERT. (2008). "HIV & AIDS in Brazil." Retrieved 30 November, 2008, from <<http://www.avert.org/aids-brazil.htm>>

AVERT. (2008). "Needle exchanges." Retrieved 30 November, 2008, from <http://www.avert.org/needle-exchange.htm>

Rossi, D., S. Harris, et al. (2009). *The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs"*. Open Society Institute – International Harm Reduction Development Program. New York.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	No
Comments	
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.
When was agonist OST first available?	
Reference	

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	No
Comments	
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.
When was MMT first available?	
Reference	

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	No
Comments	
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.
When was BMT first available?	
Reference	

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	No
Comments	
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	OST not available		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < ">http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B30 000 865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	0	0	0

OST 8: Number of sites providing MMT

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < ">http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	0	0	0

OST 9: Number of sites providing BMT

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < ">http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	0	0	0

OST 10: Number of sites providing other forms of agonist OST

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Brazilian Ministry of Health. "PCAP (Pesquisa de Conhecimentos, Atitudes e Práticas na População Brasileira de 15 a 54 anos, 2008 [Survey on Knowledge, Attitudes and Practices of the Brazilian Population, aged 15-54, 2008])." from (partial data available on-line at < http://www.aids.gov.br/main.asp?View={CEBD192A-348E-4E7E-8735-B3000865D1C}&Mode=1 >).		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High
	0	0	0

OST 11: Number of all clients in any OST at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 12: Number of all clients in MMT at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 13: Number of all clients in BMT at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	0	0	0

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	0	0	0

OST 16: Number of IDUs in MMT at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	0	0	0

OST 17: Number of IDUs in BMT at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	0	0	0

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	0	0	0

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High
	0	0	0

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	0	0	0

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	0	0	0

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	0	0	0

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported	OST not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High
	0	0	0

OST: All documents reviewed

No references recorded

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	125 196 545 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	125 196 545 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	Detoxification available but number not known		
Year of reported data	2006		
Reference	Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	125 196 545 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?	Yes		
Number of sites - data reported	Residential rehabilitation present		
Year of reported data	2004		
Reference	Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." BMC Public Health 6(1): 54.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	121 421 994 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2004		
Reference	Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." BMC Public Health 6(1): 54.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	121 421 994 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2004		
Reference	Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." BMC Public Health 6(1): 54.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	121 421 994 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	2143 NA meetings per week (Includes 145 meetings in Grande Sao Paulo Racion and 318 meetings in Southern Brazil region)		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	2143		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	3.03	3.96	5.38

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymours present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	Unspecified		
Number of sites - data reported	Outpatient drug treatment centres		
Year of reported data	2004		
Reference	Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." BMC Public Health 6(1): 54.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	121 421 994 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	Drug treatment available but number of IDUs in treatment not known		
Year of reported data	2004		
Reference	Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." BMC Public Health 6(1): 54.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	121 421 994 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	Drug treatment available but number of clients in treatment not known		
Year of reported data	2004		
Reference	Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." BMC Public Health 6(1): 54.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	121 421 994 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	375 000	510 000	666 500
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High

ODT: All documents reviewed

Brazilian Ministry of Health, Health Surveillance Secretariat, et al. (2008). Targets and Commitments made by the Member-States at the United Nation General Assembly Special Session on HIV/AIDS.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Des Jarlais, D., T. Perlis, et al. (2006). "Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II." *BMC Public Health* 6(1): 54.

Ministry Of Health Brazil (2008). Treatment and prevention of problems related to the use of alcohol and other drugs.

Pan American Health Organization (2005). Presentation delivered during the Technical Advisory Committee on HIV/AIDS/STI Technical Advisory Committee on HIV/AIDS/STI República Dominicana.

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2008
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	383 testing and counselling centres		
Year of reported data	2008		
Reference	Brazilian Ministry of Health, Health Surveillance Secretariat, et al. (2008). Targets and Commitments made by the Member-States at the United Nation General Assembly Special Session on HIV/AIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	383		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	128 738 842 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	398 000	540 500	706 500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	0.54	0.71	0.96

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	
Reference	
Data reported for both male and female IDUs	
Adjustments	
Final/Adjusted data	
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

T&C: All documents reviewed

Brazilian Ministry of Health, Health Surveillance Secretariat, et al. (2008). Targets and Commitments made by the Member-States at the United Nation General Assembly Special Session on HIV/AIDS.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Pan American Health Organization (2005). Presentation delivered during the Technical Advisory Committee on HIV/AIDS/STI Technical Advisory Committee on HIV/AIDS/STI República Dominicana.

UNAIDS (2006). High coverage sites - HIV prevention among injecting drug users in transitional and developing countries. UNAIDS best practice collection. Geneva.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	662 sites		
Year of reported data	2009		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	662		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	130 461 732 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	403 000	548 000	716 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	18	48	78
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	72 540	263 040	558 480
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	0.92	1.21	1.64
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	1.19	2.52	9.13

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	2974 IDUs started on ARVs between 2000 and 2006		
Year of reported data	2006		
Reference	Monica Malta PC		
Adjustments	This is a cumulative figure, for the purpose of this review assumed that all those who started ARVs were still alive and receiving treatment at end of observation period in 2006		
Final/Adjusted data (to be used as indicator numerator)	2974		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	125 196 545 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	18	48	78
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	69 660	252 480	535 860
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	0.55	1.18	4.27

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	No restrictions
Year of reported data	2008
Reference	Brazilian Ministry of Health, Health Surveillance Secretariat, et al. (2008). Targets and Commitments made by the Member-States at the United Nation General Assembly Special Session on HIV/AIDS.

ARV: All documents reviewed

(2008). Speech by Mr. JVR Prasada Rao at the Opening Ceremony of the "Response Beyond Borders" First Asian Consultation on the Prevention of HIV Related to Drug USE, 28 January 2008. First Asian Consultation.

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

AVERT. (2008). "HIV & AIDS in Brazil." Retrieved 30 November, 2008, from <<http://www.avert.org/aids-brazil.htm>>

Ball, A. L. (2007). "Universal access to HIV/AIDS treatment for injecting drug users: keeping the promise." *International Journal of Drug Policy*

Brazilian Ministry of Health, Health Surveillance Secretariat, et al. (2008). Targets and Commitments made by the Member-States at the United Nation General Assembly Special Session on HIV/AIDS.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

International Harm Reduction Association (2008). Harm Reduction and Human Rights: The Global Response to Injection-Driven HIV Epidemics:

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

6. Condoms

Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	Yes
Comments	Damage Reduction Programs (PRD) provide condoms for IDUs
Year	2005
Reference	Fonseca, E. M. d., A. Nunn, et al. (2007). "[Decentralization, AIDS, and harm reduction: the implementation of public policies in Rio de Janeiro, Brazil]." <i>Cadernos de Saude Publica</i> 23(9): 2134-44.

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Damage Reduction Programs (PRD) provide condoms for IDUs 150 DRPs		
Year of reported data	2006		
Reference	Fonseca, E. M. d., A. Nunn, et al. (2007). "[Decentralization, AIDS, and harm reduction: the implementation of public policies in Rio de Janeiro, Brazil]." <i>Cadernos de Saude Publica</i> 23(9): 2134-44. Rossi, D., S. Harris, et al. (2009). <i>The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs"</i> . Open Society Institute – International Harm Reduction Development Program. New York.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	150		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	125 196 545 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	0.22	0.29	0.39

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	Condom programs for IDUs present but number not known		
Year of reported data	2006		
Reference	Fonseca, E. M. d., A. Nunn, et al. (2007). "[Decentralization, AIDS, and harm reduction: the implementation of public policies in Rio de Janeiro, Brazil]." <i>Cadernos de Saude Publica</i> 23(9): 2134-44. Rossi, D., S. Harris, et al. (2009). <i>The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs"</i> . Open Society Institute – International Harm Reduction Development Program. New York.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.31	0.42	0.55
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	125 196 545 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	387 000	526 000	687 000
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

Condoms: All documents reviewed

Bastos, F. I., M. Malta, et al. (2006). "Assessing needle exchange operations in a poor Brazilian community." *Substance Use & Misuse* 41(6-7):

Bastos, F., M. Malta, et al. (2006). "Assessing Needle Exchange Operations in a Poor Brazilian Community." *Substance use & misuse* 41(6): 937-

Burrows, D. (2006). "Advocacy and coverage of needle exchange programs: results of a comparative study of harm reduction programs in Brazil, Bangladesh, Belarus, Ukraine, Russian Federation, and China." *Cadernos de Saude Publica* 22(4): 871-9.

Burrows, D. (2006). High coverage sites: HIV prevention among injecting drug users in transitional and developing countries: case studies. UNAIDS best practice collection, UNAIDS.

Fonseca, E. M. d., A. Nunn, et al. (2007). "[Decentralization, AIDS, and harm reduction: the implementation of public policies in Rio de Janeiro, Brazil]." *Cadernos de Saude Publica* 23(9): 2134-44.

Pan American Health Organization (2005). Presentation delivered during the Technical Advisory Committee on HIV/AIDS/STI Technical Advisory Committee on HIV/AIDS/STI República Dominicana.